-DOCSTART- -X- O
Inappropriate -X- _ O
platelet -X- _ O
aggregation -X- _ O
creates -X- _ O
a -X- _ O
cardiovascular -X- _ O
risk -X- _ O
that -X- _ O
is -X- _ O
largely -X- _ O
managed -X- _ O
with -X- _ O
thienopyridines -X- _ O
and -X- _ O
aspirin. -X- _ O
Although -X- _ O
effective -X- _ O
, -X- _ O
these -X- _ O
drugs -X- _ O
carry -X- _ O
risks -X- _ O
of -X- _ O
increased -X- _ O
bleeding -X- _ O
and -X- _ O
drug -X- _ O
‘resistance’ -X- _ O
, -X- _ O
underpinning -X- _ O
a -X- _ O
drive -X- _ O
for -X- _ O
new -X- _ O
antiplatelet -X- _ O
agents. -X- _ O
To -X- _ O
discover -X- _ O
such -X- _ O
drugs -X- _ O
, -X- _ O
one -X- _ O
strategy -X- _ O
is -X- _ O
to -X- _ O
identify -X- _ O
a -X- _ O
suitable -X- _ O
druggable -X- _ O
target -X- _ O
and -X- _ O
then -X- _ O
find -X- _ O
small -X- _ O
molecules -X- _ O
that -X- _ O
modulate -X- _ O
it. -X- _ O
A -X- _ O
good -X- _ O
and -X- _ O
unexploited -X- _ O
target -X- _ O
is -X- _ O
the -X- _ O
platelet -X- _ O
collagen -X- _ O
receptor -X- _ O
, -X- _ O
GPVI -X- _ O
, -X- _ O
which -X- _ O
promotes -X- _ O
thrombus -X- _ O
formation. -X- _ O
To -X- _ O
identify -X- _ O
inhibitors -X- _ B-Outcome
of -X- _ I-Outcome
GPVI -X- _ I-Outcome
that -X- _ O
are -X- _ O
safe -X- _ O
and -X- _ O
bioavailable -X- _ O
, -X- _ O
we -X- _ O
docked -X- _ O
a -X- _ O
FDA- -X- _ O
approved -X- _ O
drug -X- _ O
library -X- _ O
into -X- _ O
the -X- _ O
GPVI -X- _ O
collagen-binding -X- _ O
site -X- _ O
in -X- _ O
silico. -X- _ O
We -X- _ O
now -X- _ O
report -X- _ O
that -X- _ O
losartan -X- _ B-Outcome
and -X- _ I-Outcome
cinanserin -X- _ I-Outcome
inhibit -X- _ I-Outcome
GPVI-mediated -X- _ I-Outcome
platelet -X- _ I-Outcome
activation -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
selective -X- _ I-Outcome
, -X- _ I-Outcome
competitive -X- _ I-Outcome
and -X- _ I-Outcome
dose- -X- _ I-Outcome
dependent -X- _ I-Outcome
manner. -X- _ I-Outcome
This -X- _ O
mechanism -X- _ O
of -X- _ O
action -X- _ O
likely -X- _ O
underpins -X- _ O
the -X- _ O
cardioprotective -X- _ O
effects -X- _ O
of -X- _ O
losartan -X- _ O
that -X- _ O
could -X- _ O
not -X- _ O
be -X- _ O
ascribed -X- _ O
to -X- _ O
its -X- _ O
antihypertensive -X- _ O
effects. -X- _ O
We -X- _ O
have -X- _ O
, -X- _ O
therefore -X- _ O
, -X- _ O
identified -X- _ B-Outcome
small -X- _ I-Outcome
molecule -X- _ I-Outcome
inhibitors -X- _ I-Outcome
of -X- _ I-Outcome
GPVI-mediated -X- _ I-Outcome
platelet -X- _ I-Outcome
activation -X- _ I-Outcome
, -X- _ O
and -X- _ O
also -X- _ O
demonstrated -X- _ O
the -X- _ O
utility -X- _ O
of -X- _ O
structure-based -X- _ B-Intervention
repurposing -X- _ I-Intervention
. -X- _ O

